With great pleasure we present you with the relevant Virodene^® PO58 documentation.

Virodene^® PO58, a novel, non-invasive ‘New Generation’ drug, was invented and developed in South Africa as a safe and effective immune system enhancer/modulator.

International, accredited and world-renowned Clinical Research Organizations (CRO’s) conducted the Clinical Trials according to ICH guidelines for Good Clinical Practice (GCP); thus ensuring the validity and credibility of clinical trial data/results. These results include the statistical analyses of Virodene^® PO58’s safety, efficacy and pharmacokinetic profile.

Virodene^® PO58 is an affordable, internationally patented ‘Transdermal Patch’ which is conveniently applied to a patient’s skin, once a week, for a period of eight hours.

On this web site you will find the history of Virodene^® PO58, as well as the results of a Pilot Study; a Phase I and a Phase II Clinical Trial on healthy and HIV/AIDS infected human volunteers

New Drug Registration (NDR) is common practice for a drug showing promise in treating life-threatening diseases such as HIV/AIDS, after or even during a Phase II Clinical Trial. As the Phase II Clinical Trials have proven Virodene^® PO58 safe and effective in the treatment of HIV/AIDS, its global registration and distribution is of paramount importance.

We are offering Exclusive Territorial Product Distribution Rights to carefully selected parties, to jointly address the HIV/AIDS Pandemic effectively and efficiently on a global scale.

This product is unique, patented and affordable within the vast, largely untapped target-markets, offering the Prospective Distributor exclusivity, security, profitability and historical purpose.

This project’s humanitarian relevance is incalculable worldwide. You have the opportunity to make a dramatically vital difference in the lives of millions of people.

It would be an honor should you join us in this challenging mission and exciting venture.